Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

KRSAKorsana Biosciences, Inc.

Nasdaq · CIK 0001755237
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts262

Identity from submissions API

NameKorsana Biosciences, Inc.
CIK0001755237
TickersKRSA
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN831895370
LEI—
Fiscal year end1231
State of incorporationMA MA
Phone(781) 516-2325
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • Cyclerion Therapeutics, Inc. (2018-10-09T00:00:00.000Z → 2026-08-27T00:00:00.000Z)
Business address
203 CRESCENT STREET
BLDGS. #3/3A/4, SUITE 503
WALTHAM
MA
02453
MA
Mailing address
203 CRESCENT STREET
BLDGS. #3/3A/4, SUITE 503
WALTHAM
MA
02453
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

401 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-20 144 xsl144X01/primary_doc.xml 0001950047-26-011416 001-38787 261580407 33 5128
2026-11-20 144 xsl144X01/primary_doc.xml 0001950047-26-011406 001-38787 261579888 33 4879
2026-11-19 8-K 8-K 5.07 0001193125-26-468661 001-38787 261575312 34 168090 1 1
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-128696 005-90979 261563690 34 11788
2026-11-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-464095 005-90979 261563518 34 131315
2026-11-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001274173-26-000284 005-90979 261558586 34 13079
2026-11-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000902219-26-000330 005-90979 261557735 34 17460
2026-11-16 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-005049 005-90979 261555104 34 15478
2026-11-10 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000019617-26-000402 005-90979 261538482 34 6905
2026-11-09 S-8 S-8 0001193125-26-453743 333-299932 261536650 33 303404 1 1
2026-11-05 10-Q 10-Q 0001193125-26-448636 001-38787 261524892 34 9796509 1 1
2026-11-05 8-K 8-K 2.02,9.01 0001193125-26-448535 001-38787 261524707 34 324333 1 1
2026-10-22 144 xsl144X01/primary_doc.xml 0001950047-26-010364 001-38787 261478933 33 6585
2026-10-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001493152-26-047257 005-90979 261463401 34 9114
2026-10-15 DEF 14A DEF 14A 0001193125-26-422893 001-38787 261463232 34 1061607
2026-10-07 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-002345 005-90979 261446098 34 11732
2026-10-05 PRE 14A PRE 14A 0001193125-26-414133 001-38787 261440535 34 1060994
2026-09-23 144 xsl144X01/primary_doc.xml 0001950047-26-009776 001-38787 261401511 33 6523
2026-09-22 144 xsl144X01/primary_doc.xml 0001950047-26-009757 001-38787 261397464 33 5756
2026-09-18 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000950142-26-002568 005-90979 261392012 34 84002
2026-09-18 144 xsl144X01/primary_doc.xml 0001950047-26-009679 001-38787 261391536 33 4991
2026-09-16 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001903360-26-000015 005-90979 261382403 34 6879
2026-09-15 SCHEDULE 13D xslSCHEDULE_13D_X02/primary_doc.xml 0001738048-26-000069 005-90979 261381520 34 49508
2026-09-11 SCHEDULE 13D xslSCHEDULE_13D_X02/primary_doc.xml 0001193125-26-389417 005-90979 261375275 34 161167
2026-09-11 8-K 8-K 1.01,2.01,2.02,3.02,3.03,5.01,5.02,5.03,5.05,5.06,7.01,9.01 0001193125-26-389318 001-38787 261374665 34 2479729 1 1
2026-09-10 4 4 0001193125-26-388146 5654
2026-09-10 4 4 0001193125-26-388144 6510
2026-09-10 4 4 0001193125-26-388142 13665
2026-09-10 4 4 0001193125-26-388136 6456
2026-09-10 3 3 0001193125-26-388127 21743
2026-09-10 3 3 0001193125-26-388126 17792
2026-09-10 3 3 0001193125-26-388123 16314
2026-09-10 3 3 0001193125-26-388120 16467
2026-09-10 3 3 0001193125-26-388115 13226
2026-09-10 3 3 0001193125-26-388112 32754
2026-09-10 3 3 0001193125-26-388110 23213
2026-09-10 3 3 0001193125-26-388094 17540
2026-08-27 8-K 8-K 5.07,8.01,9.01 0001193125-26-369426 001-38787 261324861 34 202109 1 1
2026-08-25 425 425 0001193125-26-365166 001-38787 261315998 34 29967
2026-08-25 8-K 8-K 8.01 0001193125-26-365150 001-38787 261315962 34 153516 1 1
2026-08-18 4 4 0001193125-26-355721 7617
2026-08-18 4 4 0001193125-26-355707 9085
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-097419 005-90979 261284490 34 15136
2026-08-14 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001172661-26-003423 005-90979 261275804 34 14815
2026-08-12 425 425 0001193125-26-346989 001-38787 261268076 34 292852
2026-08-10 425 425 0001193125-26-342584 001-38787 261259241 34 269212
2026-08-06 425 425 0001193125-26-338459 001-38787 261250496 34 363849
2026-08-04 10-Q 10-Q 0001193125-26-332842 001-38787 261238916 34 5936092 1 1
2026-08-03 425 425 0001193125-26-330785 001-38787 261234229 34 43042
2026-07-24 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-002441 333-295175 261202719 33 1716
2026-07-24 424B3 424B3 0001193125-26-316138 333-295175 261201775 33 13067837
2026-07-22 S-4/A S-4/A 0001193125-26-312558 333-295175 261194476 33 25916317 1 1
2026-07-20 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001193125-26-309245 005-90979 261187904 34 8300
2026-07-20 4 4 0001193125-26-309048 10287
2026-07-10 425 425 0001193125-26-301054 001-38787 261169526 34 9223042
2026-07-10 S-4/A S-4/A 0001193125-26-299933 333-295175 261166643 33 26494824 1 1
2026-06-09 S-4/A S-4/A 0001193125-26-263731 333-295175 261076146 33 23789640 1 1
2026-05-12 10-Q 10-Q 0001193125-26-219478 001-38787 26968749 34 5609608 1 1
2026-05-07 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000315066-26-001385 005-90979 26951553 34 11279
2026-04-30 10-K/A 10-K/A 0001193125-26-194204 001-38787 26920299 34 889802 1 1
2026-04-20 S-4 S-4 0001193125-26-162177 333-295175 26873192 33 22376214 1 1
2026-04-01 425 425 0001193125-26-137985 001-38787 26828623 34 9763351
2026-04-01 8-K 8-K 1.01,5.01,5.02,7.01,9.01 0001193125-26-137909 001-38787 26828288 34 10299752 1 1
2026-03-30 10-K 10-K 0001193125-26-132193 001-38787 26814700 34 9113388 1 1
2026-02-17 8-K 8-K 7.01,9.01 0001193125-26-053035 001-38787 26636382 34 184300 1 1
2026-01-06 8-K 8-K 1.01,7.01,9.01 0001193125-26-003509 001-38787 26509492 34 8657270 1 1
2025-12-01 8-K 8-K 8.01 0001193125-25-304067 001-38787 251540645 34 137458 1 1
2025-11-12 10-Q 10-Q 0001193125-25-277749 001-38787 251473449 34 6661975 1 1
2025-11-12 10-K/A 10-K/A 0001193125-25-277621 001-38787 251472926 34 8865662 1 1
2025-10-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001493152-25-018450 005-90979 251400823 34 17519
2025-09-23 8-K 8-K 1.01,7.01,9.01 0001193125-25-213332 001-38787 251333796 34 5632862 1 1
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001641172-25-024017 005-90979 251218779 34 7523
2025-08-11 4 4 0000950170-25-106532 5614
2025-08-05 10-Q 10-Q 0000950170-25-103123 001-38787 251185465 34 5970262 1 1
2025-06-18 8-K 8-K 5.07,9.01 0001193125-25-142765 001-38787 251057490 34 160605 1 1
2025-05-15 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-001628 333-287006 25956817 33 1715
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001641172-25-010930 005-90979 25953345 34 7068
2025-05-13 CORRESP filename1.htm 0001193125-25-118816 6934
2025-05-12 UPLOAD filename1.pdf 0000000000-25-005035 333-287006 40042
2025-05-07 8-K 8-K 1.01,9.01 0001193125-25-115089 001-38787 25922845 34 417354 1 1
2025-05-07 424B5 424B5 0001193125-25-115085 333-284690 25922810 33 358881
2025-05-06 S-3 S-3 0001193125-25-113869 333-287006 25918094 33 341709
2025-05-06 10-Q 10-Q 0000950170-25-064493 001-38787 25917454 34 5395155 1 1
2025-04-29 DEFA14A DEFA 14A 0001140361-25-016374 001-38787 25889134 34 1382054
2025-04-29 DEF 14A DEF 14A 0001140361-25-016370 001-38787 25889090 34 4657756 1 1
2025-03-28 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000950170-25-047124 005-90979 25788492 34 9772
2025-03-27 4 4 0000950170-25-046280 7431
2025-03-27 4 4 0000950170-25-046099 4760
2025-03-25 8-K 8-K 1.01,3.02,9.01 0001193125-25-062612 001-38787 25768879 34 517990 1 1
2025-03-04 10-K 10-K 0000950170-25-032037 001-38787 25704604 34 9943461 1 1
2025-02-12 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000427 333-284690 25616931 33 1722
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-018782 005-90979 25614523 34 14840
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-018622 005-90979 25613852 34 6174
2025-02-12 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000315066-25-000869 005-90979 25612546 34 11275
2025-02-10 CORRESP filename1.htm 0001193125-25-023605 6802
2025-02-07 UPLOAD filename1.pdf 0000000000-25-001353 333-284690 40118
2025-02-04 S-3 S-3 0001193125-25-020077 333-284690 25588967 33 406771
2024-12-17 8-K 8-K 1.01,7.01,9.01 0001193125-24-280125 001-38787 241553713 34 225601 1 1
2024-12-06 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-24-006852 005-90979 241532267 34 9071
2024-11-25 4 xslF345X05/ownership.xml 0000902664-24-006775 7893
2024-11-14 10-Q 10-Q 0000950170-24-127116 001-38787 241463109 34 7052598 1 1
2024-08-07 4 4 0000950170-24-092733 5578
2024-08-07 8-K 8-K 7.01,9.01 0001193125-24-195410 001-38787 241181414 34 177907 1 1
2024-08-07 10-Q 10-Q 0000950170-24-092257 001-38787 241181335 34 6391238 1 1
2024-07-12 SC 13G/A SC 13G/A 0001193125-24-178653 005-90979 241115421 34 166138
2024-06-14 8-K 8-K 5.07,9.01 0001193125-24-161591 001-38787 241044706 34 163602 1 1
2024-05-07 10-Q 10-Q 0000950170-24-054602 001-38787 24922490 34 5459549 1 1
2024-04-29 DEFA14A DEFA14A 0001140361-24-022986 001-38787 24891181 34 958282
2024-04-29 DEF 14A DEF 14A 0001140361-24-022981 001-38787 24891088 34 1881887
2024-04-18 8-K 8-K 8.01,9.01 0001193125-24-100763 001-38787 24854339 34 148583 1 1
2024-03-11 3 3 0000950170-24-029219 3569
2024-03-05 10-K 10-K 0000950170-24-025935 001-38787 24720587 34 10040572 1 1
2024-02-14 SC 13G/A formsc13ga.htm 0001493152-24-006650 005-90979 24637805 34 75812
2024-02-09 SC 13G/A SC 13G/A 0001193125-24-030268 005-90979 24616027 34 164323
2024-02-09 SC 13G/A filing.txt 0000315066-24-001049 005-90979 24611484 34 8027
2024-01-26 4 4 0000950170-24-007920 7522
2024-01-26 4 4 0000950170-24-007917 4894
2024-01-22 SC 13G/A CYCLERION THERAPEUTICS, INC. 0000902664-24-000479 005-90979 24548663 34 60889
2023-12-28 UPLOAD filename1.pdf 0000000000-23-014145 39703
2023-12-12 CORRESP filename1.htm 0001193125-23-293378 85760
2023-12-11 3 3 0000950170-23-069443 3902
2023-12-07 3 3 0000950170-23-068795 4106
2023-12-07 3/A 3/A 0000950170-23-068792 4475
2023-12-05 SC 13D/A SC 13D/A 0001104659-23-123609 005-90979 231466470 34 116822
2023-12-04 8-K 8-K 5.02,7.01,9.01 0001193125-23-288498 001-38787 231464230 34 170106 1 1
2023-12-04 3 3 0000950170-23-067744 4032
2023-12-04 4 4 0000950170-23-067740 9330
2023-12-04 4 4 0000950170-23-067738 9301
2023-12-04 4 4 0000950170-23-067736 6546
2023-12-04 4 4 0000950170-23-067734 4734
2023-12-01 8-K 8-K 5.02,7.01,9.01 0001193125-23-286790 001-38787 231457559 34 182283 1 1
2023-11-28 UPLOAD filename1.pdf 0000000000-23-012909 47178
2023-11-24 8-K 8-K 5.02 0001193125-23-282705 001-38787 231436193 34 147142 1 1
2023-11-13 10-Q 10-Q 0000950170-23-063023 001-38787 231399314 34 8589101 1 1
2023-10-23 8-K 8-K 5.02,9.01 0001140361-23-049190 001-38787 231340451 34 246406 1 1
2023-09-05 SC 13G formsc13g.htm 0001493152-23-031649 005-90979 231235714 34 74658
2023-08-11 4 FORM 4 SUBMISSION 0000899243-23-018047 10837
2023-07-31 S-8 S-8 0001140361-23-036839 333-273530 231124568 33 101390
2023-07-28 10-Q 10-Q 0000950170-23-035558 001-38787 231123758 34 7122712 1 1
2023-07-19 8-K 8-K 5.07,9.01 0001140361-23-035245 001-38787 231097623 34 187340 1 1
2023-07-12 8-K 8-K 8.01 0000950170-23-032664 001-38787 231084349 34 443584 1 1
2023-06-27 8-K 8-K 5.02 0000950170-23-030168 001-38787 231048131 34 191872 1 1
2023-06-20 DEFM14A DEFM14A 0001140361-23-030510 001-38787 231025993 34 4222172
2023-06-09 PREM14A PREM14A 0001140361-23-029172 001-38787 231006395 34 4267990
2023-06-01 8-K 8-K 8.01,9.01 0000950170-23-025693 001-38787 23984704 34 230015 1 1
2023-05-25 D xslFormDX01/primary_doc.xml 06b 0001140361-23-026623 021-482661 23960506 33 9754
2023-05-25 8-K 8-K 3.02,5.03,9.01 0001140361-23-026621 001-38787 23960422 34 1476715 1 1
2023-05-23 SC 13D/A SC 13D/A 0001104659-23-063613 005-90979 23948887 34 35788
2023-05-22 4 xslF345X04/form4.xml 0001140361-23-026101 10415
2023-05-15 8-K 8-K 3.03,5.03,5.07,7.01,8.01,9.01 0001140361-23-024768 001-38787 23924005 34 486478 1 1
2023-05-12 SC 13D/A SC 13D/A 0001104659-23-059462 005-90979 23913397 34 44776
2023-05-12 10-Q 10-Q 0000950170-23-021448 001-38787 23912748 34 6034122 1 1
2023-05-12 DEFA14A DEFA14A 0001140361-23-024220 001-38787 23912738 34 680147
2023-05-12 8-K 8-K 1.01,2.02,3.02,7.01,8.01,9.01 0001140361-23-024218 001-38787 23912734 34 1061104 1 1
2023-04-03 DEFA14A DEFA14A 0001140361-23-015811 001-38787 23793263 34 5203944
2023-04-03 DEF 14A DEF 14A 0001140361-23-015808 001-38787 23793195 34 2727936
2023-04-03 8-K 8-K 7.01,9.01 0000950170-23-011500 001-38787 23791051 34 250372 1 1
2023-04-03 SC 13D/A SC 13D/A 0001104659-23-040535 005-90979 23790616 34 242084
2023-03-22 PRE 14A PRE 14A 0001140361-23-013099 001-38787 23753596 34 2840425
2023-03-22 10-K 10-K 0000950170-23-009223 001-38787 23753549 34 10372253 1 1
2023-03-22 8-K 8-K 2.02,9.01 0000950170-23-009221 001-38787 23753526 34 245032 1 1
2023-02-09 SC 13G/A filing.txt 0000315066-23-001464 005-90979 23601759 34 8088
2023-01-13 SC 13G CYCLERION THERAPEUTICS, INC. 0000902664-23-000260 005-90979 23529116 34 77283
2022-11-29 8-K 8-K 3.01 0000950170-22-025791 001-38787 221432753 34 190086 1 1
2022-11-22 8-K 8-K 8.01,9.01 0000950170-22-025613 001-38787 221410872 34 236651 1 1
2022-11-21 SC 13D/A SC 13D/A 0001104659-22-120818 005-90979 221406547 34 31986
2022-11-03 10-Q 10-Q 0000950170-22-021966 001-38787 221358932 34 6948052 1 1
2022-10-21 SC 13D sc13d13606002_10212022.htm 0000921895-22-002849 005-90979 221324374 34 148399
2022-10-06 8-K 8-K 2.05,7.01,9.01 0000950170-22-019330 001-38787 221297125 34 263460 1 1
2022-09-30 8-K 8-K 5.02 0000950170-22-019124 001-38787 221284939 34 185905 1 1
2022-08-10 S-8 S-8 0001140361-22-029095 333-266739 221152408 33 120501
2022-08-09 10-Q 10-Q 0000950170-22-016032 001-38787 221148187 34 6603657 1 1
2022-08-09 8-K 8-K 2.02,9.01 0000950170-22-016016 001-38787 221148067 34 261699 1 1
2022-07-28 8-K 8-K 7.01,9.01 0000950170-22-013289 001-38787 221112996 34 3078515 1 1
2022-07-27 4/A FORM 4/A 0001140361-22-027144 5188
2022-07-26 4 FORM 4 0001140361-22-026995 4889
2022-07-26 3 FORM 3 0001140361-22-026990 10745
2022-07-26 8-K 8-K 5.02,7.01,9.01 0001140361-22-026908 001-38787 221104872 34 188399 1 1
2022-06-16 4 FORM 4 0001140361-22-023335 4967
2022-06-16 4 FORM 4 0001140361-22-023334 4904
2022-06-16 4 FORM 4 0001140361-22-023333 4899
2022-06-16 4 FORM 4 0001140361-22-023332 4900
2022-06-16 4 FORM 4 0001140361-22-023331 4942
2022-06-16 4 FORM 4 0001140361-22-023330 4886
2022-06-16 4 FORM 4 0001140361-22-023329 4849
2022-06-15 8-K 8-K 5.07 0000950170-22-011675 001-38787 221017789 34 215002 1 1
2022-06-10 8-K 8-K 7.01,9.01 0000950170-22-011430 001-38787 221007615 34 5826182 1 1
2022-06-03 8-K 8-K 3.01 0000950170-22-011148 001-38787 22994214 34 185935 1 1
2022-05-04 10-Q 10-Q 0000950170-22-007378 001-38787 22891537 34 5949100 1 1
2022-05-04 8-K 8-K 2.02,9.01 0000950170-22-007369 001-38787 22891408 34 258529 1 1
2022-04-26 DEFA14A DEFA14A 0001140361-22-015850 001-38787 22851817 34 1606511
2022-04-26 DEF 14A DEF 14A 0001140361-22-015849 001-38787 22851816 34 2030802
2022-02-24 10-K 10-K 0000950170-22-001958 001-38787 22670886 34 10100616 1 1
2022-02-24 8-K 8-K 2.02,9.01 0000950170-22-001956 001-38787 22670800 34 258405 1 1
2022-02-11 SC 13G/A slatepath-cycn123121a1.htm 0001172661-22-000383 005-90979 22621896 34 56243
2022-02-11 SC 13G/A SC 13G/A 0001193125-22-035595 005-90979 22616598 34 185809
2022-02-09 SC 13G/A SC 13G/A 0001193125-22-032020 005-90979 22604522 34 91370
2022-02-09 SC 13G/A filing.txt 0000315066-22-000939 005-90979 22604256 34 8242
2022-01-24 4 FORM 4 0001140361-22-002458 4983
2022-01-24 4 FORM 4 0001140361-22-002456 4991
2022-01-24 4 FORM 4 0001140361-22-002453 7218
2022-01-24 4 FORM 4 0001140361-22-002451 4987
2021-12-10 4 FORM 4 0001140361-21-041210 12632
2021-12-10 4 FORM 4 0001140361-21-041209 11821
2021-12-10 4 FORM 4 0001140361-21-041208 12426
2021-11-09 10-Q 10-Q 0000950170-21-003724 001-38787 211391936 34 7149277 1 1
2021-11-09 8-K 8-K 2.02,9.01 0000950170-21-003725 001-38787 211391926 34 259186 1 1
2021-10-28 8-K 8-K 5.02 0001140361-21-035774 001-38787 211359113 34 164459 1 1
2021-09-30 8-K 8-K 7.01,9.01 0001140361-21-033010 001-38787 211293814 34 11641693 1 1
2021-09-07 UPLOAD filename1.pdf 0000000000-21-010836 39393
2021-08-27 10-Q/A 10-Q/A 0001140361-21-029588 001-38787 211219602 34 236544 1 1
2021-08-27 10-Q/A 10-Q/A 0001140361-21-029585 001-38787 211219433 34 232016 1 1
2021-08-27 10-K/A 10-K/A 0001140361-21-029579 001-38787 211219321 34 261500 1 1
2021-08-27 CORRESP filename1.htm 0001140361-21-029575 8981
2021-08-24 UPLOAD filename1.pdf 0000000000-21-010341 43795
2021-08-19 8-K 8-K 5.02 0001140361-21-028904 001-38787 211190847 34 159624 1 1
2021-07-30 S-8 S-8 0001140361-21-026239 333-258316 211133006 33 88378
2021-07-29 10-Q 10-Q 0001564590-21-039205 001-38787 211128321 34 7911701 1 1
2021-07-29 8-K 8-K 2.02,9.01 0001564590-21-039201 001-38787 211128286 34 320074 1 1
2021-06-28 4 FORM 4 0001140361-21-022583 12318
2021-06-28 4 FORM 4 0001140361-21-022578 12286
2021-06-28 4 FORM 4 0001140361-21-022575 11548
2021-06-28 4 FORM 4 0001140361-21-022569 11619
2021-06-28 4 FORM 4 0001140361-21-022553 12186
2021-06-28 4 FORM 4 0001140361-21-022549 11619
2021-06-28 4 FORM 4 0001140361-21-022547 4849
2021-06-28 4 FORM 4 0001140361-21-022544 12214
2021-06-25 8-K 8-K 5.07 0001140361-21-022349 001-38787 211048334 34 31243
2021-06-24 424B4 424B4 0001140361-21-022140 333-257145 211041201 33 679388
2021-06-23 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-06-23 16:00:00 9999999995-21-002479 333-257145 211040484 33 1674
2021-06-23 S-3/A S-3/A 0001140361-21-021998 333-257145 211037853 33 773448
2021-06-21 CORRESP filename1.htm 0001140361-21-021690 8450
2021-06-21 UPLOAD filename1.pdf 0000000000-21-007538 40163
2021-06-17 D xslFormDX01/primary_doc.xml 06b 0001567619-21-012331 021-403393 211025460 33 13387
2021-06-16 S-3 S-3 0001140361-21-021236 333-257145 211022058 33 1024848
2021-06-07 4 FORM 4 SUBMISSION 0000899243-21-022327 11641
2021-06-07 4 FORM 4 0001140361-21-020090 7132
2021-06-07 SC 13D/A SC 13DA 0001140361-21-020086 005-90979 211000425 34 50410
2021-06-07 4 xslF345X03/ownership.xml 0000902664-21-003032 7585
2021-06-04 8-K 8-K 1.01,3.02,9.01 0001140361-21-019923 001-38787 21997011 34 56873
2021-05-19 3 FORM 3 0001140361-21-018080 9899
2021-05-14 SC 13D SC 13D 0001140361-21-017445 005-90979 21925632 34 73273
2021-05-10 4 FORM 4 0001140361-21-016532 7390
2021-05-06 4 FORM 4 0001140361-21-016304 14208
2021-05-04 8-K 8-K 1.02,9.01 0001140361-21-015739 001-38787 21889196 34 45556
2021-04-30 10-Q 10-Q 0001564590-21-022522 001-38787 21877758 34 5041161 1
2021-04-28 DEFA14A DEFA14A 0001140361-21-014661 001-38787 21861285 34 1603359
2021-04-28 DEF 14A DEF 14A 0001140361-21-014660 001-38787 21861280 34 1882261
2021-04-27 8-K 8-K 2.02,7.01,9.01 0001140361-21-014426 001-38787 21856202 34 10088531
2021-04-26 8-K 8-K 5.02,7.01,9.01 0001140361-21-014205 001-38787 21851868 34 37648
2021-03-19 8-K/A 8-K/A 8.01,9.01 0001140361-21-009236 001-38787 21756418 34 31169
2021-03-18 8-K 8-K 8.01,9.01 0001140361-21-009117 001-38787 21755078 34 30348
2021-03-01 4 FORM 4 0001140361-21-006649 5021
2021-03-01 4 FORM 4 0001140361-21-006641 5038
2021-02-25 10-K 10-K 0001564590-21-008434 001-38787 21676432 34 9104287 1
2021-02-16 SC 13G/A SC 13G/A 0001193125-21-042136 005-90979 21631452 34 203573
2021-02-12 SC 13G SCHEDULE 13/G FILING BY CYCLERION ON BEHALF OF MFN PARTNERS 0000904454-21-000194 005-90979 21629357 34 132214
2021-02-08 SC 13G/A filing.txt 0000315066-21-000940 005-90979 21599454 34 8333
2021-02-05 SC 13G/A SC 13G/A 0001193125-21-030235 005-90979 21594671 34 35011
2021-01-13 8-K 8-K 2.02,7.01,9.01 0001193125-21-007746 001-38787 21525076 34 13756272
2021-01-11 3 FORM 3 0001140361-21-000823 26594
2021-01-11 3 FORM 3 0001140361-21-000821 35907
2020-12-30 3 FORM 3 0001140361-20-029981 23143
2020-12-30 4 FORM 4 0001140361-20-029869 4909
2020-12-21 8-K 8-K 5.02 0001193125-20-323185 001-38787 201404724 34 21101
2020-11-12 4 FORM 4 SUBMISSION 0001209191-20-058031 5215
2020-11-10 4 FORM 4 SUBMISSION 0001209191-20-057768 4890
2020-11-06 4 FORM 4 SUBMISSION 0001209191-20-057302 5316
2020-11-05 10-Q 10-Q 0001564590-20-050844 001-38787 201288595 34 5409687 1
2020-10-14 8-K FORM 8-K 8.01,9.01 0001104659-20-114699 001-38787 201238215 34 2545816
2020-10-01 8-K FORM 8-K 8.01 0001104659-20-110691 001-38787 201214394 34 18187
2020-09-22 S-8 FORM S-8 0001104659-20-107118 333-248957 201187625 33 67095
2020-09-09 SC 13G/A us23255m1053_090920.txt 0000834237-20-010209 005-90979 201166524 34 12179
2020-09-03 424B5 424B5 0001104659-20-102276 333-240095 201159803 33 751905
2020-09-03 8-K FORM 8-K 1.01,9.01 0001104659-20-102011 001-38787 201158209 34 275414
2020-08-17 424B4 424B4 0001104659-20-095986 333-242334 201108918 33 1379643
2020-08-14 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2020-08-14 16:00:00 9999999995-20-002162 333-242334 201107821 33 1674
2020-08-12 UPLOAD filename1.pdf 0000000000-20-007365 40099
2020-08-12 CORRESP filename1.htm 0001104659-20-093961 9356
2020-08-11 D xslFormDX01/primary_doc.xml 06b 0001104659-20-093290 021-372991 201092442 33 13591
2020-08-10 3 xslF345X02/ownership.xml 0000902664-20-002945 13511
2020-08-10 SC 13G CYCLERION THERAPEUTICS, INC. 0000902664-20-002944 005-90979 201089576 34 76612
2020-08-07 S-3 FORM S-3 0001104659-20-091997 333-242334 201085344 33 1514074
2020-08-03 8-K FORM 8-K 2.02,9.01 0001104659-20-089685 001-38787 201069847 34 94177
2020-08-03 10-Q FORM 10-Q 0001104659-20-089193 001-38787 201067074 34 4372727 1
2020-07-31 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2020-07-31 16:00:00 9999999995-20-001998 333-240095 201067702 33 1674
2020-07-30 CORRESP filename1.htm 0001104659-20-088538 7254
2020-07-30 S-3/A FORM S-3/A 0001104659-20-088412 333-240095 201061908 33 724817
2020-07-30 UPLOAD filename1.pdf 0000000000-20-006988 40190
2020-07-24 S-3 S-3 0001104659-20-086517 333-240095 201047574 33 1122559
2020-07-09 8-K FORM 8-K 2.02,7.01,9.01 0001104659-20-082390 001-38787 201020913 34 16504457
2020-06-18 8-K FORM 8-K 5.07,7.01,9.01 0001104659-20-074702 001-38787 20973318 34 66505
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037589 5225
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037587 5247
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037580 5261
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037575 5248
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037573 5262
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037571 5329
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037568 5266
2020-06-18 4 FORM 4 SUBMISSION 0001209191-20-037566 5265
2020-05-04 10-Q 10-Q 0001104659-20-056280 001-38787 20845772 34 3719977 1
2020-04-23 DEFA14A DEFA14A 0001140361-20-009597 001-38787 20811700 34 2127590
2020-04-23 DEF 14A DEF 14A 0001140361-20-009594 001-38787 20811651 34 2054181
2020-04-14 8-K FORM 8-K 2.02,7.01,8.01,9.01 0001104659-20-046446 001-38787 20791975 34 9561613
2020-04-02 4 FORM 4 SUBMISSION 0001209191-20-022657 9547
2020-03-12 10-K FORM 10-K 0001104659-20-032554 001-38787 20709568 34 6800408 1
2020-03-05 8-K FORM 8-K 1.01,9.01 0001104659-20-029761 001-38787 20691557 34 78816
2020-02-25 4 FORM 4 SUBMISSION 0001209191-20-012430 5398
2020-02-14 SC 13G SC 13G 0001193125-20-038302 005-90979 20620312 34 35024
2020-02-14 SC 13G/A PRIMARY DOCUMENT 0001654954-20-001573 005-90979 20614632 34 69291
2020-02-13 SC 13G/A SCH 13G/A FILING BY MFN PARTNERS FOR ISSUER CYCLERION THERAPEUTICS, TO BE FILED 0000904454-20-000173 005-90979 20611881 34 114736
2020-02-07 SC 13G filing.txt 0000315066-20-000899 005-90979 20585552 34 8281
2020-02-07 SC 13G us23255m1053_020620.txt 0000834237-20-008046 005-90979 20584694 34 13263
2020-02-03 SC 13G SC 13G 0001193125-20-023050 005-90979 20569434 34 208646
2020-01-13 8-K FORM 8-K 7.01,9.01 0001104659-20-003162 001-38787 20522629 34 4335916
2019-12-31 4 FORM 4 SUBMISSION 0001209191-19-062322 7350
2019-12-27 SC 13G cycn13g.htm 0000935836-19-000672 005-90979 191314076 34 49646
2019-11-26 4 FORM 4 SUBMISSION 0001209191-19-058165 6132
2019-11-26 4 FORM 4 SUBMISSION 0001209191-19-058163 6118
2019-11-26 4 FORM 4 SUBMISSION 0001209191-19-058162 6134
2019-11-26 4 FORM 4 SUBMISSION 0001209191-19-058158 6133
2019-11-19 4 FORM 4 SUBMISSION 0001209191-19-057112 4964
2019-11-12 4 FORM 4 SUBMISSION 0001209191-19-056008 5402
2019-11-12 10-Q 10-Q 0001104659-19-062590 001-38787 191209192 34 5037483 1
2019-10-30 8-K 8-K 2.02,2.05,8.01,9.01 0001104659-19-057505 001-38787 191177856 34 2252870
2019-09-25 8-K 8-K 5.02,9.01 0001104659-19-051352 001-38787 191114543 34 139764
2019-09-20 4/A FORM 4/A SUBMISSION 0001209191-19-050311 24178
2019-09-20 4/A FORM 4/A SUBMISSION 0001209191-19-050309 22766
2019-09-20 4/A FORM 4/A SUBMISSION 0001209191-19-050308 13041
2019-08-12 10-Q 10-Q 0001104659-19-045323 001-38787 191017283 34 4845193 1
2019-08-12 8-K 8-K 2.02,9.01 0001104659-19-045189 001-38787 191014414 34 149762
2019-07-12 4 FORM 4 SUBMISSION 0001209191-19-041920 9876
2019-06-17 SC 13G PRIMARY DOCUMENT 0001654954-19-007382 005-90979 19900757 34 69485
2019-06-04 4 FORM 4 SUBMISSION 0001209191-19-034383 5264
2019-06-04 4 FORM 4 SUBMISSION 0001209191-19-034382 5265
2019-06-04 4 FORM 4 SUBMISSION 0001209191-19-034379 5328
2019-06-04 4 FORM 4 SUBMISSION 0001209191-19-034376 5261
2019-06-04 4 FORM 4 SUBMISSION 0001209191-19-034375 5247
2019-06-04 4 FORM 4 SUBMISSION 0001209191-19-034373 5260
2019-06-04 4 FORM 4 SUBMISSION 0001209191-19-034371 5246
2019-06-04 4 FORM 4 SUBMISSION 0001209191-19-034369 5224
2019-05-13 10-Q 10-Q 0001104659-19-028981 001-38787 19819283 34 2427727 1
2019-05-13 8-K 8-K 2.02,9.01 0001104659-19-028766 001-38787 19816877 34 116084
2019-05-01 4 FORM 4 SUBMISSION 0001209191-19-026820 5493
2019-05-01 3 FORM 3 SUBMISSION 0001209191-19-026819 6271
2019-04-23 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2019-04-23 16:00:00 9999999995-19-000803 333-230944 19762516 33 1673
2019-04-23 424B3 424B3 0001047469-19-002505 333-230944 19762149 33 4042814
2019-04-22 CORRESP filename1.htm 0001104659-19-022786 12050
2019-04-18 S-1 S-1 0001047469-19-002389 333-230944 19756556 33 4130627
2019-04-17 D xslFormDX01/primary_doc.xml 06b 0001104659-19-021921 021-337559 19752810 33 16108
2019-04-16 UPLOAD filename1.pdf 0000000000-19-007200 40004
2019-04-11 SC 13G 13G FILING FOR MFN AND CYCLERION - CREATED AND UPDATED ON 4.9.19 0000904454-19-000355 005-90979 19743522 34 155677
2019-04-10 4 FORM 4 SUBMISSION 0001209191-19-024237 11581
2019-04-10 4 FORM 4 SUBMISSION 0001209191-19-024236 9037
2019-04-09 DRS filename1.htm 0000912057-19-000160 377-02587 19739956 33 4148884
2019-04-09 8-K 8-K 8.01,9.01 0001104659-19-020379 001-38787 19738508 34 45891
2019-04-04 4/A FORM 4/A SUBMISSION 0001209191-19-023727 5190
2019-04-03 4 FORM 4 SUBMISSION 0001209191-19-023566 10997
2019-04-03 4/A FORM 4/A SUBMISSION 0001209191-19-023565 10112
2019-04-03 4 FORM 4 SUBMISSION 0001209191-19-023556 36354
2019-04-03 3 FORM 3 SUBMISSION 0001209191-19-023554 6211
2019-04-03 3 FORM 3 SUBMISSION 0001209191-19-023522 6235
2019-04-03 4 FORM 4 SUBMISSION 0001209191-19-023521 32181
2019-04-03 3 FORM 3 SUBMISSION 0001209191-19-023519 6189
2019-04-03 4 FORM 4 SUBMISSION 0001209191-19-023517 15876
2019-04-03 4 FORM 4 SUBMISSION 0001209191-19-023514 6658
2019-04-03 3 FORM 3 SUBMISSION 0001209191-19-023509 6154
2019-04-03 4 FORM 4 SUBMISSION 0001209191-19-023507 6657
2019-04-03 4 FORM 4 SUBMISSION 0001209191-19-023494 4722
2019-04-03 3 FORM 3 SUBMISSION 0001209191-19-023489 6182
2019-04-03 4 FORM 4 SUBMISSION 0001209191-19-023488 4718
2019-04-03 3 FORM 3 SUBMISSION 0001209191-19-023487 6163
2019-04-03 4 FORM 4 SUBMISSION 0001209191-19-023486 4704
2019-04-03 3 FORM 3 SUBMISSION 0001209191-19-023485 6162
2019-04-03 4 FORM 4 SUBMISSION 0001209191-19-023461 4732
2019-04-03 3 FORM 3 SUBMISSION 0001209191-19-023460 6113
2019-04-03 4 FORM 4 SUBMISSION 0001209191-19-023381 8004
2019-04-03 3 FORM 3 SUBMISSION 0001209191-19-023363 6138
2019-04-02 4 4 0001104659-19-019466 6843
2019-04-02 8-K 8-K 1.01,2.01,3.02,3.03,5.01,5.02,5.03,7.01,9.01 0001104659-19-019416 001-38787 19726059 34 5404782
2019-03-29 S-8 S-8 0001104659-19-018720 333-230615 19716993 33 690286
2019-03-19 8-K 8-K 5.02 0001104659-19-016052 001-38787 19692650 34 24493
2019-03-15 3 3 0001104659-19-014989 2780
2019-03-14 3 3 0001104659-19-014914 2840
2019-03-14 3 3 0001104659-19-014913 2830
2019-03-14 3 3 0001104659-19-014911 3727
2019-03-14 SEC STAFF ACTION filename1.pdf 9999999997-19-001156 9879
2019-03-14 UPLOAD filename1.pdf 0000000000-19-004815 45486
2019-03-14 CERT Form10_Cert_CYCN.pdf 0001354457-19-000129 001-38787 19680175 34 80402
2019-03-12 CORRESP filename1.htm 0001104659-19-014230 10490
2019-03-11 10-12B/A 10-12B/A 0001047469-19-001059 001-38787 19671059 34 4170936
2019-03-04 10-12B/A 10-12B/A 0001047469-19-000876 001-38787 19654550 34 5255789
2019-01-28 10-12B 10-12B 0001047469-19-000256 001-38787 19543863 34 7481642
2019-01-07 DRSLTR filename1.htm 0001410578-19-000010 29893
2019-01-07 DRS/A filename1.htm 0000912057-19-000008 377-02304 19513149 33 7328563
2018-12-18 UPLOAD filename1.pdf 0000000000-18-038336 51727
2018-12-06 DRSLTR filename1.htm 0001410578-18-000589 48550
2018-12-06 DRS/A filename1.htm 0000912057-18-000507 377-02304 181220070 33 4077219
2018-11-06 UPLOAD filename1.pdf 0000000000-18-034596 57713
2018-10-09 DRSLTR filename1.htm 0001410578-18-000440 11480

Latest XBRL company facts

One latest value per concept from companyfacts (262 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 45.54M 2026-11-02 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
dei EntityNumberOfEmployees Entity Number of Employees Employee 0 2019-11-15 2024 Q3 10-Q 2024-11-14 0000950170-24-127116
dei EntityPublicFloat Entity Public Float USD 5.70M 2025-06-30 2025 FY 10-K 2026-03-30 0001193125-26-132193
ffd NetFeeAmt NetFeeAmt USD 21,664.12 2026-11-09 S-8 2026-11-09 0001193125-26-453743
ffd TtlFeeAmt TtlFeeAmt USD 21,664.12 2026-11-09 S-8 2026-11-09 0001193125-26-453743
ffd TtlOfferingAmt TtlOfferingAmt USD 249.01M 2026-11-09 S-8 2026-11-09 0001193125-26-453743
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-11-09 S-8 2026-11-09 0001193125-26-453743
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 1.4 2026-07-09 S-4/A 2026-07-10 0001193125-26-299933
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 1.61M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap AccountsPayableRelatedPartiesCurrent Accounts Payable, Related Parties, Current USD 0 2021-12-31 2021 FY 10-K 2022-02-24 0000950170-22-001958
us-gaap AccountsReceivableNetCurrent Accounts Receivable, after Allowance for Credit Loss, Current USD 0 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap AccountsReceivableRelatedPartiesCurrent Accounts Receivable, Related Parties, Current USD 0 2021-12-31 2021 FY 10-K 2022-02-24 0000950170-22-001958
us-gaap AccruedBonusesCurrent Accrued Bonuses, Current USD 0 2023-12-31 2023 FY 10-K 2024-03-05 0000950170-24-025935
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 0 2023-12-31 2023 FY 10-K 2024-03-05 0000950170-24-025935
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 1.33M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap AccruedSalariesCurrent Accrued Salaries, Current USD 18,000 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-127116
us-gaap AccruedVacationCurrent Accrued Vacation, Current USD 0 2023-12-31 2023 FY 10-K 2024-03-05 0000950170-24-025935
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 126,000 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277749
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD 0 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 504.59M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 281.04M 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 2.57M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 17.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units USD 705.44M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 7.65M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap AreaOfLand Area of Land sqft 114,000 2019-04-01 2019 Q3 10-Q 2019-11-12 0001104659-19-062590
us-gaap AssetAcquisitionConsiderationTransferred AssetAcquisitionConsiderationTransferred USD 8.00M 2023-07-28 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 0 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap Assets Assets USD 462.08M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap AssetsCurrent Assets, Current USD 460.65M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 453.69M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents USD 81,000 2026-09-08 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net USD -3.28M 2026-09-08 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-09 0000950170-21-003724
us-gaap Cash Cash USD 0 2020-12-31 2020 FY 10-K 2021-02-25 0001564590-21-008434
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 456.22M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap CashAndCashEquivalentsFairValueDisclosure Cash and Cash Equivalents, Fair Value Disclosure USD 93.86M 2019-12-31 2020 Q1 10-Q 2020-05-04 0001104659-20-056280
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 456.32M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect USD 0 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-13 0001104659-19-028981
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 302.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap CashEquivalentsAtCarryingValue Cash Equivalents, at Carrying Value USD 41.10M 2022-03-31 2022 Q1 10-Q 2022-05-04 0000950170-22-007378
us-gaap CommitmentsAndContingencies Commitments and Contingencies USD 0 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 17.02M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 400.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 45.54M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 45.54M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap CommonStockValue Common Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -77,295 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest USD -3.53M 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense Deferred Compensation Arrangement with Individual, Allocated Share-based Compensation Expense USD 100,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-25 0001564590-21-008434
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 0 2023-12-31 2023 FY 10-K 2024-03-05 0000950170-24-025935
us-gaap DeferredRevenue Deferred Revenue USD 100,000 2023-03-31 2023 Q1 10-Q 2023-05-12 0000950170-23-021448
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 20,000 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 83.39M 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 0 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 57.62M 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap DeferredTaxAssetsPropertyPlantAndEquipment Deferred Tax Assets, Property, Plant and Equipment USD 1,000 2021-12-31 2021 FY 10-K 2022-02-24 0000950170-22-001958
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 10.38M 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 6.50M 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap DeferredTaxAssetsTaxDeferredExpenseOther Deferred Tax Assets, Tax Deferred Expense, Other USD 0 2022-12-31 2022 FY 10-K 2023-03-22 0000950170-23-009223
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals USD 0 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 83.39M 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 556,000 2018-12-31 2019 FY 10-K 2020-03-12 0001104659-20-032554
us-gaap DefinedBenefitPlanBenefitObligation Defined Benefit Plan, Benefit Obligation USD 0 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap DefinedBenefitPlanContributionsByEmployer Defined Benefit Plan, Plan Assets, Contributions by Employer USD 200,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap DefinedContributionPlanCostRecognized Defined Contribution Plan, Cost USD 100,000 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match pure 0.75 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap Depreciation Depreciation USD 33,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-05 0000950170-24-025935
us-gaap DerivativeLiabilityFairValueOfCollateral Derivative Liability, Fair Value of Collateral USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax USD 0 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax USD 15.75M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-13 0000950170-23-063023
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -13.42 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.3 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-04 0000950170-22-007378
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -13.42 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.048 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure 0 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent pure -0.162 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure 0 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 0 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 2.05M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount USD 200,000 2021-06-30 2021 Q2 10-Q 2021-07-29 0001564590-21-039205
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 100,000 2023-03-31 2023 Q1 10-Q 2023-05-12 0000950170-23-021448
us-gaap EquitySecuritiesFvNiCurrentAndNoncurrent EquitySecuritiesFvNiCurrentAndNoncurrent USD 5.00M 2023-03-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount USD 0 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap FutureMinimumSubleaseRentalsSaleLeasebackTransactions Future Minimum Sublease Rentals, Sale Leaseback Transactions USD 500,000 2019-10-18 2019 FY 10-K 2020-03-12 0001104659-20-032554
us-gaap GainLossOnSaleOfPropertyPlantEquipment Gain (Loss) on Disposition of Property Plant Equipment USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-22 0000950170-23-009223
us-gaap GainLossOnTerminationOfLease Gain (Loss) on Termination of Lease USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-22 0000950170-23-009223
us-gaap GainOnBusinessInterruptionInsuranceRecovery Gain on Business Interruption Insurance Recovery USD 1.32M 2025-01-01 2025-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap GainsLossesOnExtinguishmentOfDebt Gain (Loss) on Extinguishment of Debt USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-22 0000950170-23-009223
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 12,355 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap ImpairmentOfInvestments Other than Temporary Impairment Losses, Investments USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-127116
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -3.53M 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -3.53M 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 0 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest USD -3.06M 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap IncomeLossFromContinuingOperationsPerBasicShare Income (Loss) from Continuing Operations, Per Basic Share USD/shares -1.21 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap IncomeLossFromContinuingOperationsPerDilutedShare Income (Loss) from Continuing Operations, Per Diluted Share USD/shares -1.21 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap IncomeLossFromDiscontinuedOperationsNetOfTax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest USD 0 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share USD/shares 0 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share USD/shares 0 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap IncomeTaxExaminationPenaltiesAndInterestAccrued Income Tax Examination, Penalties and Interest Accrued USD 0 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 170,000 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap IncomeTaxReconciliationDispositionOfBusiness Effective Income Tax Rate Reconciliation, Disposition of Business, Amount USD 9.80M 2019-01-01 2019-12-31 2020 FY 10-K 2021-02-25 0001564590-21-008434
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD 0 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -741,000 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap IncomeTaxReconciliationNondeductibleExpense Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount USD 571,000 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 22,000 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 0 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -155,000 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap IncomeTaxReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Amount USD 0 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD 2.89M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-13 0001104659-19-028981
us-gaap IncreaseDecreaseInAccountsPayableRelatedParties Increase (Decrease) in Accounts Payable, Related Parties USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-22 0000950170-23-009223
us-gaap IncreaseDecreaseInAccountsPayableTrade Increase (Decrease) in Accounts Payable, Trade USD 1.43M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD -1.00M 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap IncreaseDecreaseInAccountsReceivableRelatedParties Increase (Decrease) in Accounts Receivable, Related Parties USD 0 2023-01-01 2023-06-30 2023 Q2 10-Q 2023-07-28 0000950170-23-035558
us-gaap IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities USD 12.64M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap IncreaseDecreaseInOtherCurrentAssets Increase (Decrease) in Other Current Assets USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap IncreaseDecreaseInOtherCurrentLiabilities Increase (Decrease) in Other Current Liabilities USD -5.27M 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-13 0001104659-19-028981
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD 0 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap IncreaseDecreaseInOtherNoncurrentLiabilities Increase (Decrease) in Other Noncurrent Liabilities USD 52,000 2019-01-01 2019-03-31 2019 Q1 10-Q 2019-05-13 0001104659-19-028981
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD 52,000 2019-01-01 2019-03-31 2020 Q1 10-Q 2020-05-04 0001104659-20-056280
us-gaap IncreaseDecreaseInPrepaidExpense Increase (Decrease) in Prepaid Expense USD -272,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap IncreaseDecreaseInPrepaidExpensesOther Increase (Decrease) in Prepaid Expenses, Other USD 3.83M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap InvestmentIncomeNonoperating Investment Income, Nonoperating USD 588,000 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-25 0001564590-21-008434
us-gaap LeaseCost Lease, Cost USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-03 0000950170-22-021966
us-gaap LeaseholdImprovementsGross Leasehold Improvements, Gross USD 6.30M 2021-06-30 2021 Q2 10-Q 2021-07-29 0001564590-21-039205
us-gaap LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate pure 0.109 2019-04-01 2019 Q3 10-Q 2019-11-12 0001104659-19-062590
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 1.58M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 24.05M 2020-12-31 2020 FY 10-K 2021-02-25 0001564590-21-008434
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 382,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 6.44M 2020-12-31 2020 FY 10-K 2021-02-25 0001564590-21-008434
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 410,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 401,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 392,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 314,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap LessorOperatingLeasePaymentsToBeReceived Lessor, Operating Lease, Payments to be Received USD 16.33M 2020-06-30 2020 Q2 10-Q 2020-08-03 0001104659-20-089193
us-gaap LessorOperatingLeasePaymentsToBeReceivedFiveYears Lessor, Operating Lease, Payment to be Received, Year Five USD 1.78M 2020-06-30 2020 Q2 10-Q 2020-08-03 0001104659-20-089193
us-gaap LessorOperatingLeasePaymentsToBeReceivedFourYears Lessor, Operating Lease, Payment to be Received, Year Four USD 1.73M 2020-06-30 2020 Q2 10-Q 2020-08-03 0001104659-20-089193
us-gaap LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths Lessor, Operating Lease, Payment to be Received, Year One USD 1.01M 2019-12-31 2019 FY 10-K 2020-03-12 0001104659-20-032554
us-gaap LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear Lessor, Operating Lease, Payment to be Received, Remainder of Fiscal Year USD 800,000 2020-06-30 2020 Q2 10-Q 2020-08-03 0001104659-20-089193
us-gaap LessorOperatingLeasePaymentsToBeReceivedThereafter Lessor, Operating Lease, Payment to be Received, after Year Five USD 8.69M 2020-06-30 2020 Q2 10-Q 2020-08-03 0001104659-20-089193
us-gaap LessorOperatingLeasePaymentsToBeReceivedThreeYears Lessor, Operating Lease, Payment to be Received, Year Three USD 1.68M 2020-06-30 2020 Q2 10-Q 2020-08-03 0001104659-20-089193
us-gaap LessorOperatingLeasePaymentsToBeReceivedTwoYears Lessor, Operating Lease, Payment to be Received, Year Two USD 1.64M 2020-06-30 2020 Q2 10-Q 2020-08-03 0001104659-20-089193
us-gaap LettersOfCreditOutstandingAmount Letters of Credit Outstanding, Amount USD 100,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap Liabilities Liabilities USD 45.56M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 462.08M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap LiabilitiesCurrent Liabilities, Current USD 44.20M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap LossContingencyAccrualAtCarryingValue Loss Contingency Accrual USD 0 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 351.92M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -297,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -49.44M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -77.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 Noncash or Part Noncash Acquisition, Other Liabilities Assumed USD 3.36M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap NoninterestExpenseDirectorsFees Noninterest Expense Directors Fees USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 4,190 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap NotesPayableCurrent Notes Payable, Current USD 0 2021-12-31 2021 FY 10-K 2022-02-24 0000950170-22-001958
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap OperatingExpenses Operating Expenses USD 81,485 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -81,485 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 0 2024-01-01 2024-09-30 2024 Q3 10-Q 2024-11-14 0000950170-24-127116
us-gaap OperatingLeaseImpairmentLoss Operating Lease, Impairment Loss USD 3.30M 2023-01-01 2023-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 1.27M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 287,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 984,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap OperatingLeasePayments Operating Lease, Payments USD 1.89M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-22 0000950170-23-009223
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 967,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap OperatingLeasesRentExpenseSubleaseRentals1 Operating Leases, Rent Expense, Sublease Rentals USD 200,000 2019-04-01 2019-06-30 2019 Q2 10-Q 2019-08-12 0001104659-19-045323
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.061 2020-12-31 2021 FY 10-K 2022-02-24 0000950170-22-001958
us-gaap OtherAccruedLiabilitiesNoncurrent Other Accrued Liabilities, Noncurrent USD 376,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap OtherAssetsCurrent Other Assets, Current USD 11,000 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 0 2023-12-31 2023 FY 10-K 2024-03-05 0000950170-24-025935
us-gaap OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax USD 0 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD 2,000 2020-01-01 2020-03-31 2021 Q1 10-Q 2021-04-30 0001564590-21-022522
us-gaap OtherLiabilitiesCurrent Other Liabilities, Current USD 5.56M 2019-03-31 2019 Q1 10-Q 2019-05-13 0001104659-19-028981
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 52,000 2019-03-31 2019 Q1 10-Q 2019-05-13 0001104659-19-028981
us-gaap OtherLongTermInvestments Other Long-term Investments USD 5.35M 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap OtherNonoperatingIncome Other Nonoperating Income USD 4,190 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap OtherSundryLiabilitiesCurrent Other Sundry Liabilities, Current USD 3.77M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap PaymentsForRestructuring Payments for Restructuring USD 1.37M 2023-01-01 2023-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 10.38M 2019-01-01 2019-12-31 2020 FY 10-K 2021-02-25 0001564590-21-008434
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 297,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap PaymentsToEmployees Payments to Employees USD 10.00M 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-03 0000950170-22-021966
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 100.00M 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2022-09-30 2023 Q3 10-Q 2023-11-13 0000950170-23-063023
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2022-09-30 2023 Q3 10-Q 2023-11-13 0000950170-23-063023
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 4.43M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 112,000 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap ProceedsFromContributedCapital Proceeds from Contributed Capital USD 46.44M 2019-01-01 2019-12-31 2020 FY 10-K 2021-02-25 0001564590-21-008434
us-gaap ProceedsFromDivestitureOfBusinesses Proceeds from Divestiture of Businesses USD 0 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap ProceedsFromIssuanceOfPreferredStockAndPreferenceStock Proceeds from Issuance of Preferred Stock and Preference Stock USD 3.05M 2023-01-01 2023-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-22 0000950170-23-009223
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 0 2024-01-01 2024-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap ProceedsFromNotesPayable Proceeds from Notes Payable USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-24 0000950170-22-001958
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-22 0000950170-23-009223
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -77.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 126,000 2025-09-30 2025 Q3 10-Q 2025-11-12 0001193125-25-277749
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 367,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 69,130 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap RestrictedCash Restricted Cash USD 101,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap RestrictedCashAndCashEquivalents Restricted Cash and Cash Equivalents USD 0 2022-03-31 2022 Q1 10-Q 2022-05-04 0000950170-22-007378
us-gaap RestrictedCashAndCashEquivalentsAtCarryingValue Restricted Cash and Cash Equivalents, Current USD 2.70M 2019-12-31 2020 FY 10-K 2021-02-25 0001564590-21-008434
us-gaap RestrictedCashAndCashEquivalentsNoncurrent Restricted Cash and Cash Equivalents, Noncurrent USD 0 2021-12-31 2021 FY 10-K 2022-02-24 0000950170-22-001958
us-gaap RestructuringCharges Restructuring Charges USD -565,000 2023-01-01 2023-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap RestructuringReserveAccrualAdjustment1 Restructuring Reserve, Accrual Adjustment USD 0 2023-01-01 2023-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap RestructuringReserveCurrent Restructuring Reserve, Current USD 0 2023-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -113.03M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap RevenueFromContractWithCustomerExcludingAssessedTax Revenue from Contract with Customer, Excluding Assessed Tax USD 2.30M 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-25 0001564590-21-008434
us-gaap RevenueFromRelatedParties Revenue from Related Parties USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-02-24 0000950170-22-001958
us-gaap RevenueRecognitionMilestoneMethodRevenueRecognized Revenue Recognition, Milestone Method, Revenue Recognized USD 200,000 2025-01-01 2025-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap Revenues Revenues USD 0 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 1.08M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap SecurityDepositLiability Security Deposit Liability USD 3.80M 2020-12-31 2021 FY 10-K 2022-02-24 0000950170-22-001958
us-gaap SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmount Settlement of Asset Retirement Obligations Through Noncash Payments, Amount USD 8.00M 2023-01-01 2023-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap SeveranceCosts1 Severance Costs USD 100,000 2024-08-01 2024-08-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 17.42M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number shares 809,417 2023-03-31 2023 Q1 10-Q 2023-05-12 0000950170-23-021448
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 1.411 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.038 2025-01-01 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 315,000 2019-09-30 2019 Q3 10-Q 2019-11-12 0001104659-19-062590
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 2.48M 2019-09-30 2019 Q3 10-Q 2019-11-12 0001104659-19-062590
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 14.84 2019-09-30 2019 Q3 10-Q 2019-11-12 0001104659-19-062590
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054602
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 150,000 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-09 0000950170-21-003724
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures shares 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054602
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054602
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 1.97 2020-01-01 2020-12-31 2021 FY 10-K 2022-02-24 0000950170-22-001958
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 1.08M 2019-09-30 2019 Q3 10-Q 2019-11-12 0001104659-19-062590
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 7,500 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054602
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 40.2 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054602
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 7.20M 2019-04-01 2019-09-30 2019 Q3 10-Q 2019-11-12 0001104659-19-062590
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 0 2024-01-01 2024-03-31 2024 Q1 10-Q 2024-05-07 0000950170-24-054602
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected employee 143 2021-01-01 2021-06-30 2021 Q2 10-Q 2021-07-29 0001564590-21-039205
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 8.18 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-12 0001104659-19-062590
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 2.01 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-11-09 0000950170-21-003724
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 13.21 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-12 0001104659-19-062590
us-gaap ShortTermBorrowings Short-term Debt USD 3.50M 2022-12-31 2022 FY 10-K 2023-03-22 0000950170-23-009223
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 391.56M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD 5.09M 2026-06-30 2026 Q2 10-Q 2026-08-04 0001193125-26-332842
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 24,250 2020-01-01 2020-12-31 2020 FY 10-K 2021-02-25 0001564590-21-008434
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 47,121 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-12 0001104659-19-062590
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 150.57M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 151.00M 2025-09-15 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap SubleaseIncome Sublease Income USD 300,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-02-24 0000950170-22-001958
us-gaap TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount USD 10.80M 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap TenantImprovements Tenant Improvements USD 2.30M 2019-09-30 2019 Q3 10-Q 2019-11-12 0001104659-19-062590
us-gaap TransferToInvestments Transfer to Investments USD 5.35M 2023-01-01 2023-12-31 2024 FY 10-K/A 2025-11-12 0001193125-25-277621
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued USD 0 2025-12-31 S-4/A 2026-07-22 0001193125-26-312558
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 26.50M 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-12 0001104659-20-032554
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 5.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 43.42M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-04 0000950170-22-007378
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 5.41M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-448636

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →